Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia
Brief Summary: This is a single arm, open-label, multi-center, phase II study to determine the efficacy and safety of CTL019 in pediatric patients with r/r B-cell ALL.


Options:
A: Arm Label: ALL (high tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (high tumor burden) dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: ALL (low tumor burden) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: CLL (ibrutinib) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 1; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL dose level 3; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Arm Label: NHL (dose dense) dose level 2; Type: EXPERIMENTAL; Interventions: Biological: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes | Intervention Type: BIOLOGICAL; Name: Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes; Assigned to Arm(s): ALL (high tumor burden) dose level 1, ALL (high tumor burden) dose level 2, ALL (high tumor burden) dose level 3, ALL (low tumor burden) dose level 1, ALL (low tumor burden) dose level 2, CLL (ibrutinib) dose level 2, CLL dose level 1, CLL dose level 2, CLL dose level 3, NHL (dose dense) dose level 2, NHL dose level 1, NHL dose level 2, NHL dose level 3
B: Arm Label: Arm A - Standard of Care (SOC); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of Care | Arm Label: Arm B - JCAR017; Type: EXPERIMENTAL; Interventions: Genetic: JCAR017 | Intervention Type: DRUG; Name: Standard of Care; Assigned to Arm(s): Arm A - Standard of Care (SOC) | Intervention Type: GENETIC; Name: JCAR017; Assigned to Arm(s): Arm B - JCAR017
C: Arm Label: Single dose of CTL019; Type: EXPERIMENTAL; Interventions: Biological: CTL019 | Intervention Type: BIOLOGICAL; Name: CTL019; Assigned to Arm(s): Single dose of CTL019
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: FBTA05 | Intervention Type: DRUG; Name: FBTA05; Assigned to Arm(s): 1

Answer: C